@Article{or.2025.060573,
AUTHOR = {GAVIN M. ANCHONDO, KYRA PARKER, ALEXIS BRUCE, ELIZABETH CORTEZ, LE SU},
TITLE = {The SS18-SSX fusion oncoprotein: Friend and foe in targeted therapy for synovial sarcoma},
JOURNAL = {Oncology Research},
VOLUME = {33},
YEAR = {2025},
NUMBER = {5},
PAGES = {1001--1005},
URL = {http://www.techscience.com/or/v33n5/60621},
ISSN = {1555-3906},
ABSTRACT = {Synovial sarcoma is a high-grade soft tissue malignancy characterized by a unique fusion gene known as SS18-SSX. The SS18-SSX fusion protein acts as an oncogenic driver of synovial sarcoma, and it has thus been commonly accepted that disruption of SS18-SSX function represents a therapeutic means of treating synovial sarcoma, but emerging evidence suggests that upon depletion of SS18-SSX, an anti-apoptotic signal surprisingly arises to protect synovial sarcoma cell survival. In this article, we discuss the controversial roles of SS18-SSX’s transcriptional activity in synovial sarcoma biology and outline a synergistic strategy for overcoming the resistance of synovial sarcoma cells to SS18-SSX targeted therapeutics.},
DOI = {10.32604/or.2025.060573}
}